Journal of International Psychiatry

[Abstract] Objective To explore the therapeutic effect of agomelatine on schizophrenia with depressive symptoms. Methods Ninety-six patients with schizophrenia and depression in our hospital from April 2019 to June 2022 were selected as the study subjects. They were randomly divided into two groups using the number table method. Forty-eight cases in the control group were treated with risperidone, and 48 cases in the observation group were treated with argomepratine on the basis of risperidone for 8 weeks. Hamilton Depression and Anxiety Scale (HAMD), HAMA, Pittsburgh Sleep Quality Index (PSQI), and Positive and Negative Symptom Scale (PANSS) were compared between the two groups before and after treatment. The occurrence of adverse reactions during treatment were recorded. Results After treatment, the HAMD, HAMA score and PSQI index of patients in the two groups were significantly reduced, and the scores in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the positive symptoms, negative symptoms and general psychopathology scores of PANSS in the two groups were significantly lower, and the negative symptoms and general psychopathology scores in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the score of positive symptoms (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Agomepratine can effectively reduce anxiety and depression in patients with schizophrenia and depression, improve sleep quality, and promote the reduction of negative symptoms and general psychopathological symptoms.

Key words Agomelatine; Schizophrenia; Depressive Symptoms; Sleep Quality